Insider Transactions in Q2 2025 at Ani Pharmaceuticals Inc (ANIP)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 22
2025
|
Thomas Haughey Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,336
+7.2%
|
-
|
|
May 22
2025
|
Patrick D Walsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,336
+5.2%
|
-
|
|
May 22
2025
|
Jeanne Thoma Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,336
+8.8%
|
-
|
|
May 22
2025
|
Renee P Tannenbaum Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,336
+13.86%
|
-
|
|
May 22
2025
|
Antonio R Pera Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,336
+10.92%
|
-
|
|
May 22
2025
|
Matthew J Leonard Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,336
+20.98%
|
-
|
|
May 15
2025
|
Ori Gutwerg SVP, GENERICS |
SELL
Open market or private sale
|
Direct |
881
-0.97%
|
$52,860
$60.07 P/Share
|
|
May 14
2025
|
Christopher Mutz HEAD OF RARE DISEASE |
SELL
Open market or private sale
|
Direct |
4,000
-3.59%
|
$240,000
$60.45 P/Share
|
|
May 13
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.5%
|
$24,800
$62.2 P/Share
|
|
May 09
2025
|
Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS |
SELL
Open market or private sale
|
Indirect |
700
-0.11%
|
$53,200
$76.83 P/Share
|
|
Apr 14
2025
|
Meredith Cook SR. VP, GENERAL COUNSEL & SEC. |
SELL
Open market or private sale
|
Direct |
400
-0.5%
|
$27,200
$68.96 P/Share
|